• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      VENCLYXTO® (venetoclax) in Acute Myeloid Leukaemia (AML)

       

      In combination with a hypomethylating agent for newly-diagnosed patients with AML who are ineligible for intensive chemotherapy1

       

       

       

      UK-VNCAML-220109 | April 2022
      1. Venclyxto Summary of Product Characteristics

      Resources

      Downloadable materials for HCPs

      Below are links to downloadable materials that may be useful to use as a reference in your routine clinical practice 

      Dosing & Administration guide

      UK-VNCAML-210092 | August 2021


      Downloadable materials for your AML patients prescribed VENCLYXTO

      Below are links to downloadable materials that may be useful to use as a reference in your routine clinical practice 

       

      VENCLYXTO AML patient booklet 

      UK-VNCAML-210066 | June 2021

      Understanding AML patient booklet

      UK-VNCAML-210069 | June 2021

      Patient wallet card
       

      UK-VNCAML-210070 | June 2021

      Patient commonly asked questions

      UK-VNCAML-210067 | June 2021


      Downloadable materials for the carers of your patients with AML

      Below are links to downloadable materials that may be useful to use as a reference in your routine clinical practice 

       

      Caregiver booklet
       

      UK-VNCAML-210065 | June 2021

      Caregiver commonly asked questions 

      UK-VNCAML-210068 | June 2021

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

      UK-VNCAML-220117. Date of preparation: April 2022.